From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Universal Influenza Antiviral Breakthrough

by Global Biodefense Staff
February 25, 2013

Influenza Antiviral Drug Binding with NeurominidaseScientists from Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) have helped to design a new drug to safeguard against epidemic and pandemic flu strains. The new antiviral agent has been proven to be effective in preventing the spread of different strains of influenza in laboratory models – including resistant strains of the virus. 

Influenza antiviral agents play important roles in modulating disease severity and in controlling pandemics while vaccines are prepared, but the development of resistance to agents like the commonly used neuraminidase inhibitor oseltamivir may limit their future utility. 

The researchers are developing a new class of specific, mechanism-based anti-influenza drug that function via the formation of a stabilized covalent intermediate in the influenza neuraminidase enzyme. In order to infect cells, flu viruses bind onto sugars on the cell surface. To be able to spread they need to remove these sugars. The new drug works by preventing the virus from removing sugars and blocking the virus from infecting more cells. 

“CSIRO researchers have shown that flu viruses continually mutate and some have become resistant to available treatments,” said Dr. Jenny McKimm-Breschkin, CSIRO scientist. “The new drug is effective against these resistant strains. As the site where the drug binds is found in all flu strains, the new drug is expected to be effective even against future flu strains.” 

Professor Steve Withers, University of British Columbia, has led the research team for the past seven years and said that although further studies are required to determine efficacy against a broader range of flu strains, the findings are extremely positive. 

“This antiviral drug would play an important role as the first line of defense in modulating disease severity and in controlling a pandemic while vaccines are prepared,” said Withers. 

The breakthrough is the result of a collaboration between scientists from CSIRO, the University of British Columbia and the University of Bath. Read more at Science: Mechanism-based Covalent Neuraminidase Inhibitors with Broad Spectrum Influenza Antiviral Activity. 

Sources: CSIRO, Science. Image credit: Magpix.

From Our Partners
Tags: AntiviralsInfluenzaPandemic

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC